IL4R and chronic rhinosinusitis with nasal polyps: These include dupilumab, an anti‐IL‐4R monoclonal antibody (mAb), mepolizumab, an anti‐IL‐5 mAb, and omalizumab, an anti‐IgE mAb which have now been approved for treating CRSwNP in the European Union.40, 41, 42